PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “MONOAMINE OXIDASE”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 379 records · Page 21Linked to original sources

Observation of two different chromophores in the resting state of monoamine oxidase B by fluorescence spectroscopy.

Catalytically active monoamine oxidase (MAO) is believed to exist as a dimer with each subunit containing a covalently attached flavin cofactor. Fluorescence spectroscopy performed on the resting state enzyme resulted in two separate fluorescence emissions at 480 nm and 530 nm with excitation maxima at lambda ex = 412 nm and lambda ex = 450 nm, respectively. Inactivation of MAO with pargyline resulted in concomitant loss of the absorbance at 450 nm without change in the 412 nm absorption; there also was a decrease in the emission intensity at 530 nm, while the emission at 480 nm remained unchanged. The 480 nm emission decreased and the 530 nm emission intensity increased, when the enzyme was heat denatured in the presence of NaDodSO4. From these results, it is clear that there are two different chromophores present in the resting state enzyme; the 530 nm chromophore is consistent with an oxidized flavin, while the 480 nm chromophore could be a flavin semiquinone.

Animals↗

Human monoamine oxidase. Lack of brain and platelet correlation.

Monoamine oxidase (MAO) exists in two forms, MAO A and MAO B. Both are present in human brain, but the human platelet contains only MAO B. We studied whether individual variations in the activity of human platelet MAO B reflect individual variations in cerebral cortical MAO activities. Optimal conditions were determined for the measurement of MAO activities in both the platelet and cerebral cortex, obtained from 14 patients with epilepsy during clinically indicated neurosurgery. There was no significant correlation between the activities of MAO B in the cerebral cortex and platelets of these patients. Platelet MAO B activities also failed to correlate significantly with cerebral cortical MAO A activities. However, there was a significant positive correlation between cerebral cortical MAO A and MAO B activities. Individual variations in platelet MAO B activities do not reflect individual variations in either cerebral cortical MAO B or MAO A activities in patients with epilepsy who undergo neurosurgery.

Adolescent↗

In vivo properties of N-(2-aminoethyl)-5-halogeno-2-pyridinecarboxamide 18F- and 123I-labelled reversible inhibitors of monoamine oxidase B.

The reversible and highly selective monoamine oxidase B (MAO-B) inhibitor Ro 19-6327, a picolinic acid derivative, was selected for the development of new radiopharmaceuticals, whereby in place of Cl either 123I or 18F was introduced. The respective labelling procedures have been described earlier. In this study, some metabolic properties were investigated. Blood and urine samples were analysed, and halogenated picolinylglycine, a more hydrophilic compound, was identified as the main metabolite. This shows that the amine is oxidised to the respective carboxylate, but the intermediate imine or aldehyde that was proposed earlier could not be detected. First experiments with single photon emission tomography and positron emission tomography (PET) showed that the iodo compound can be used to investigate MAO-B in vivo while the fluoro compound is accumulated in the brain to such a low degree that no PET studies can be performed. We conclude that the main reason for the poor uptake of the fluoro compound is its lower lipophilicity as compared to the iodo compound and, to a lesser degree, its metabolism, which is similar for both compounds.

Adult↗

R-(-)-Deprenyl inhibits monocytic THP-1 cell neurotoxicity independently of monoamine oxidase inhibition.

R-(-)-Deprenyl (deprenyl, selegiline), a monoamine oxidase B (MAO-B) inhibitor, delays progression of Parkinson's disease. This action could be mediated by inhibition of MAO-B but there may also be unrelated mechanisms. Direct neuroprotective and antiapoptotic actions of deprenyl have previously been observed in vitro. Here we describe an antineurotoxic action of deprenyl which is independent of direct neuronal effects. We employed a previously described assay in which human neuroblastoma SH-SY5Y cells are exposed to cell-free supernatants of stimulated human monocytic THP-1 cells. Deprenyl reduced the secretion of neurotoxic products by such stimulated cells in a concentration-dependent manner, while the MAO inhibitors iproniazid, isocarboxazid, nialamide, tranylcypromine, phenelzine, and clorgyline were without effect. No antineurotoxic action was observed when deprenyl was added directly to SH-SY5Y cells. Messenger RNAs for MAO-A and MAO-B were not detected in THP-1 cells by reverse transcriptase-polymerase chain reaction analysis of total RNA extracts. Such mRNAs were easily detected in extracts of SH-SY5Y cells under comparable conditions. MAO enzymatic activity was also undetectable in THP-1 cell lysates, while it was readily observed in SH-SY5Y cells. It was concluded that the effect of deprenyl on THP-1 cells was not mediated by MAO and that deprenyl itself was not protecting neurons. These data suggest that deprenyl may have utility in neurodegenerative diseases due to its antineurotoxic actions.

Alzheimer Disease↗

Structure-activity relations in the oxidation of phenethylamine analogues by recombinant human liver monoamine oxidase A.

The interaction of recombinant human liver monoamine oxidase A (MAO A) with a series of phenethylamine substrate analogues has been investigated by steady-state and stopped-flow kinetic techniques. Substrate analogues with para substituents exhibit large deuterium kinetic isotope effect on k(cat), on k(cat)/K(m), and on the limiting rate of enzyme reduction in reductive half-reaction experiments. These kinetic isotope effect values range from 5 to 10 with the exception of tyramine, which exhibited smaller steady-state isotope effects (2.3-3.5) than that observed on the rate of flavin reduction (6.9). The stopped-flow data show that imine release from the reduced enzyme is slower than the rate of catalytic turnover. Phenethylamine oxidation by MAO A can be described as the C-H bond cleavage step being rate limiting in catalysis and with oxygen reacting with the reduced enzyme-imine complex. In the case of tyramine, the product release from the oxidized enzyme-imine complex contributes to the rate limitation in catalysis. The binding affinities of a series of para-substituted phenethylamine analogues to MAO A show an increase in affinity of the deprotonated amine with increasing van der Waals volume of the substituent. The limiting rate of enzyme reduction decreases with increasing van der Waals volume of the substituent in a linear manner with no observable electronic contribution as observed previously with benzylamine reduction of MAO A [Miller, J. R., and Edmondson, D. E. (1999) Biochemistry 38, 13670-13683]. Examination of side chain analogues of phenethylamine show 3-phenylpropylamine to be oxidized 2.5-fold more slowly and bound 75-fold more tightly than phenethylamine. 4-Phenylbutylamine is not a substrate for MAO A but is a good competitive inhibitor with a K(i) value of 31 +/- 5 microM. Analysis of the effect of alkyl side chain alterations on binding affinities of a series of arylalkylamine analogues taken from this study and from the literature show a linear correlation with the Taft steric value (E(s)) of the side chain. These results suggest that the binding site for the aryl ring is identical for phenethylamine and for benzylamine analogues and that steric interactions of the alkyl side chain with the enzyme strongly contribute to the binding affinities of a series of reversible inhibitors of MAO A.

Flow Injection Analysis↗

[Effect of D,L-malic acid dibenzylhydrazide on changes in the antioxidizing activity of lipids and monoamine oxidase activity in mouse organs].

Administration of dibenzylhydracide of D,L-malic acid (inhibitor of monoamine oxidase) into animals caused not only inhibition but also transformation of the mitochondrial monoamine oxidase activity, which acquired the property to deaminate histamine. Effect of the monoamine oxidase inhibitor on the antioxidative activity of lipids from mouse liver and brain tissues was studied. Effect of the dose administered and of the period of its action after administration were characterized. Influence of the inhibitor on oxidation of methyloleate was also studied in a model system. The data obtained suggest that the transformation-producing effect of the substance was not related to its immudiate action on the enzyme molecule but was apparently due to its influence on the intensity of lipid peroxidation in membranes.

Animals↗

Monoamine oxidase inhibitors and serotonin uptake inhibitors: differential effects on [3H]serotonin binding sites in rat brain.

Rats were administered either monoamine oxidase inhibitors or serotonin uptake inhibitors for either 1, 4 or 16 days. The binding of [3H]serotonin to brain homogenates and the concentration of serotonin in brain was measured at these times. Treatment with inhibitors of serotonin uptake did not change the specific binding of [3H]serotonin in either cerebral cortex or hippocampus, nor did it produce any consistent alterations in the concentration of serotonin in the cerebral cortex. In contrast, monoamine oxidase inhibitors capable of inhibiting A-type monoamine oxidase significantly decreased [3H]serotonin binding after both 4 and 16 days of treatment; serotonin concentrations were significantly elevated at all time intervals. Inhibitors of B-type monoamine oxidase had no effect on either [3H]serotonin binding or serotonin concentrations in cerebral cortex. The reduction in labeled serotonin binding caused by monoamine oxidase inhibitors is due to a decrease in the maximum number of specific binding sites with no change in the affinity of the binding sites for labeled serotonin.

Amitriptyline↗

Irreversible inhibition of monoamine oxidase by some components of cigarette smoke.

Inhibitory activity towards monoamine oxidase has been found in a solution of cigarette smoke. The inhibition was irreversible. When tissue slices of rat lung were incubated in the cigarette smoke solution or alternatively, exposed directly to cigarette smoke, monoamine oxidase activities were reduced drastically. Similarly, human saliva after cigarette smoking also exhibits considerable MAO inhibitory activity. When the amine substrates p-tyramine, serotonin and beta-phenylethylamine were incubated with the cigarette smoke solution, lipophilic adducts were formed non-enzymatically. The irreversible inhibition of MAO by cigarette smoke may well be related to the low platelet MAO associated with cigarette smokers as previously reported. The implication of such cigarette smoke-caused reduction of MAO activity in relation to Parkinsonism is discussed.

Animals↗

Human serum monoamine oxidase.

A study on serum monoamine oxidase (MAO) levels in fibrotic disease processes led us to investigate patients with moderate to severe burns. Strikingly low serum MAO activity was found in patients with relatively recent, severe injuries. So far, we have no explanation to offer for the phenomena observed.

Burns↗

Monoamine oxidase inhibitors and elective surgery.

Monoamine oxidase inhibitor use is considered a contraindication for elective surgery. We reviewed 32 patients on a regimen of isocarboxazid 10 mg daily who underwent elective surgery. Their anesthetic management, postanesthesia outcome, and pharmacology are described.

Adult↗

Topographic immunocytochemical mapping of monoamine oxidase-A, monoamine oxidase-B and tyrosine hydroxylase in human post mortem brain stem.

Immunocytochemical demonstration of monoamine oxidase-A, monoamine oxidase-B and tyrosine hydroxylase was performed in the human brain stem using monoclonal antibodies to monoamine oxidase-A and monoamine oxidase-B and polyclonal antibodies to tyrosine hydroxylase. In most of the brain areas examined, except the serotonergic dorsal nucleus of raphe, the noradrenergic locus coeruleus and the dorsal efferent nucleus of vagus, tyrosine hydroxylase-positive neurons were in greater number than monoamine oxidase-A-stained or monoamine oxidase-B-stained neurons. The dorsal nucleus of raphe showed no tyrosine hydroxylase immunoreactivity, but reacted positively to serotonin- and monoamine oxidase-B antibodies, while monoamine oxidase-A staining was moderate. In none of the investigated brain areas did neurons exclusively react with monoamine oxidase-B antibodies without expressing monoamine oxidase-A in a few neurons, while in some areas neurons expressed both monoamine oxidase-A and tyrosine hydroxylase (locus coeruleus; dorsal efferent nucleus of vagus). The oculomotor nucleus stained only with monoamine oxidase-A antibodies, substantia nigra neurons reacted only with tyrosine hydroxylase antibodies. Glial staining in most of the brain areas examined seemed, with slight differences, to have the same intensity with monoamine oxidase-A and monoamine oxidase-B antibodies used. No glial staining was obtained with tyrosine hydroxylase antibodies.

Aged↗

Plasma monoamine oxidase levels in mammals.

Plasma monoamine oxidase (MAO) levels in ruminants and non-ruminants including man are reported. The mean MAO levels in units are, goat 6699.7+/-367.4; cattle 6272.9+/-9.257.4; camel 5166.0+/-666.8; sheep 4831.4+/-543.8; buffaloe 4045.8+/-387.3; rabbit 837.0+/-19.3; dog 441.8+/-55.5 and man 20.0+/-2.8 respectively.

Animals↗

Patterns of monoamine oxidase maturation in mouse brain.

Monoamine oxidase (MAO) was assayed in mouse brain between the ages of 1 day postpartum and adulthood. Two substrates, 5-hydroxytryptamine (5-HT) and tryptamine, were used and assays were done with and without thermal inactivation at 50 degrees C for 10 min. Relative patterns of MAO maturation were found including one form that decreased with increasing age.

Age Factors↗

Platelet monoamine oxidase activity and psychopathy.

Platelet monoamine oxidase (MAO) activity appears to be correlated to certain diagnostic subgroups and symptom patterns. A group of criminal offenders hospitalized for forensic psychiatric assessment were studied. Male nurses and construction workers were used as controls. Patients who were diagnosed as psychopaths according to the criteria of Cleckley had significantly lower platelet MAO activity than the control group of construction workers.

Adult↗

Alterations in the pattern of amine excretion in man produced by a monoamine oxidase inhibitor.

The administration of monoamine oxidase inhibitors produces an increase in the urinary excretion of many amines for which efficient alternate routes of metabolism are not available. These include tryptamine, paratyramine, and a "metatyramine-like" substance. The inhibitors can therefore be used to detect previously unsuspected pathways of amino acid decarboxylation. The finding that the excretions of norepinephrine, epinephrine, 3,4-dihydroxyphenylethylamine, and possible serotonin are not appreciably affected are consistent with previous reports of the existence of alternative metabolic routes.

Amines↗

Comparative membrane locations and activities of human monoamine oxidases expressed in yeast.

Human monoamine oxidases A and B were expressed under the control of a galactose inducible promoter in Saccharomyces cerevisiae. The two MAO isoenzymes were found located in the yeast mitochondrial outer membrane, probably in different orientations as suggested by controlled proteolysis experiments. A high level of both human MAO-A or -B activities is measured in intact mitochondria without the need for any detergent solubilisation step. The substrate and inhibitor selectivities of the membrane-bound MAOs are highly similar to those of purified human enzymes. The level of MAO-B activity, however, is selectively lowered when bound to the membrane.

Base Sequence↗

Platelet monoamine oxidase in affective disorders.

Platelet monoamine oxidase (MAO) activity was determined with tryptamine as substrate for 61 drug-free patients who had a primary major depressive disorder and for 32 normal controls. Although there were no significant differences between the mean platelet MAO activity of 19 bipolar patients (4.94 nmoles/hr/mg of protein), 42 unipolar patients (4.97 nmoles), and the controls (4.78 nmoles), an analysis of variance indicated that the variance of the bipolar group was significantly greater than that of the other groups. This suggests that there may be subgroups of bipolar patients that differ in their platelet MAO activity but that appear to be distinct from the bipolar I vs bipolar II classification.

Adult↗

Platelet monoamine oxidase and plasma amine oxidase in psychiatric patients.

Platelet monoamine oxidase (MAO) and plasma amine oxidase (PAO) activities were determined in 70 normal controls and 76 psychiatric patients. Platelet MAO activity did not differ between the normal controls and patients diagnosed as schizophrenic or primary affective illness, although there was a strong trend for chronic schizophrenics to have lower MAO activity. Schizophrenic patients with Schneiderian-type hallucinatiions had significantly lower MAO activity than normal controls or schizophrenic patients who did not hallucinate. There was no relationship between hallucinations and platelet MAO activity in patients with affective psychoses. Paranoid schizophrenics did not have significantly different MAO activity from nonparanoid schizophrenics. PAO activity was generally lower in all diagnostic groups than in normal controls, but the results were statistically significant only for acute schizophrenics.

Affective Disorders, Psychotic↗